REPERTOIRE IMMUNE MEDICINES
Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.
REPERTOIRE IMMUNE MEDICINES
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.repertoire.com
Total Employee:
101+
Status:
Active
Contact:
(617) 863-3650
Total Funding:
257.28 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible IPv6 Akamai Hosted JobVite
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Eyebiotech
Eyebiotech is a privately held ophthalmology biotechnology company.
Facegenics
Facegenics is a medical technology company.
Platelet BioGenesis
Platelet BioGenesis specializes in the fields of biotechnology, platelets, and drug discovery.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
Current Employees Featured
Founder
Investors List
Invus
Invus investment in Series B - Repertoire Immune Medicines
PSP Investments
PSP Investments investment in Series B - Repertoire Immune Medicines
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - Repertoire Immune Medicines
Flagship Pioneering
Flagship Pioneering investment in Series B - Repertoire Immune Medicines
Alaska Permanent Fund
Alaska Permanent Fund investment in Series B - Repertoire Immune Medicines
JDRF T1D Fund
JDRF T1D Fund investment in Venture Round - Repertoire Immune Medicines
Flagship Pioneering
Flagship Pioneering investment in Series A - Repertoire Immune Medicines
Key Employee Changes
| Date | New article |
|---|---|
| 2021-06-03 | Anne Walker Joins Repertoire Immune Medicines as Executive Vice President and Chief Financial Officer |
Official Site Inspections
http://www.repertoire.com Semrush global rank: 3.77 M Semrush visits lastest month: 3.57 K
- Host name: msp-a100-3227.arcusvps.net
- IP address: 162.247.141.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Repertoire Immune Medicines" on Search Engine
About Us • Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat …See details»
Overview • Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat …See details»
BMS pays $65M to expand Repertoire of autoimmune assets
Apr 29, 2024 Bristol Myers Squibb is placing a $65 million bet on Repertoire Immune Medicines’ approach to resetting the immune system. The deal, which features up to …See details»
Repertoire Immune Medicines - Crunchbase Company Profile
Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune …See details»
Repertoire Immune Medicines Secures $189M Financing to …
Apr 13, 2021 Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to …See details»
Repertoire Immune Medicines Enters Collaboration to Advance …
May 26, 2021 CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create …See details»
$1.8 Billion Collaboration Developing Tolerizing Vaccines for ...
Apr 30, 2024 Repertoire® Immune Medicines announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines …See details»
Repertoire Immune Medicines (@RepertoireIM) / Twitter
Mar 11, 2020 Repertoire Immune Medicines is a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease. Cambridge, MA repertoire.com …See details»
Repertoire Immune Medicines Launches Type 1… | Flagship …
Mar 25, 2020 Repertoire Immune Medicines, a Flagship Pioneering company, is a clinical stage biotechnology company working to unleash the remarkable power of the human …See details»
Repertoire® Immune Medicines and Bristol Myers Squibb
CAMBRIDGE, Mass., April 29, 2024. Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted …See details»
Repertoire® Immune Medicines Enters New Research ... - BioSpace
Jul 14, 2022 Repertoire Immune Medicines is a clinical-stage biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell …See details»
Repertoire® Immune Medicines and Bristol Myers Squibb …
Apr 29 2024 11:00 BST. Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune …See details»
Pipeline • Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat …See details»
Repertoire Immune Medicines AG – Swiss Biotech
Canton. Zurich. Facts & figures. Type of organization. Private company. Year of foundation. 2018. Number of employees in Switzerland. 1-9. Key business. R&D. Sales & marketing …See details»
Flagship's Repertoire reveals culls, cuts and new CEO - Fierce …
Nov 7, 2022 Biotech. UPDATE: Flagship-founded Repertoire reveals culls, cuts and a new CEO marking dismal clinical start. By Max Bayer Nov 7, 2022 10:47am. Repertoire …See details»
Repertoire Immune Medicines - Funding, Financials, Valuation
Repertoire Immune Medicines has raised a total of. $257.3M. in funding over 5 rounds. Their latest funding was raised on Apr 13, 2021 from a Series B round. Repertoire …See details»
Repertoire® Immune Medicines and Bristol Myers Squibb …
Apr 29, 2024 Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to …See details»
Press Releases • Repertoire Immune Medicines
Jun 3, 2021 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer. Read More. …See details»
Repertoire Immune Medicines | CipherBio
Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune …See details»
Repertoire® Immune Medicines and Bristol Myers Squibb …
CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire ® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T …See details»